Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.06 - Poster Session 1 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 59
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.06-035 - VEGF-A 165 family of isoforms as predictive biomarkers in patients with non-squamous non-small cell lung cancer (NSCLC) treated with bevacizumab.
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading...
-
+
P1.11 - Poster Session 1 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 45
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.11-004 - Phase II study of carboplatin-docetaxel-bevacizumab as front-line treatment in patients with stage IV non-squamous non-small-cell lung cancer. Analysis of the bevacizumab (BVZ) maintenance population
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading... -
+
P1.11-005 - EVEREST Study: Evolution of disease-related symptoms of patients (p) with advanced non-small cell lung cancer (NSCLC) and its correlation with response to first-line (1L) treatment.
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading...
-
+
P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 50
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.06-042 - Thymidylate synthase expression as predictive biomarker of pemetrexed sensitivity in advanced thoracic cancer patients.
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading...
-
+
P2.09 - Poster Session 2 - Combined Modality
- Type: Poster Session
- Track: Combined Modality
- Presentations: 18
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.09-004 - Phase II study of sequential versus concurrent chemotherapy and radiotherapy in poor risk patients with inoperable stage III non-small cell lung cancer (NSCLC): final results of the Spanish Lung Cancer Group 00-05 study
09:30 - 09:30 | Author(s): F. Cardenal
- Abstract
Loading...
-
+
O15 - NSCLC - Chemotherapy II
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:G. Richardson
- Coordinates: 10/29/2013, 10:30 - 12:00, Bayside Auditorium A, Level 1
-
+
O15.02 - The Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) (NCT00617656/GECP-BREC)
10:40 - 10:50 | Author(s): R. Rosell
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.05 - Poster Session 3 - Preclinical Models of Therapeutics/Imaging
- Type: Poster Session
- Track: Biology
- Presentations: 22
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.05-011 - Targeting epithelial to mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer
09:30 - 09:30 | Author(s): I. Cañadas
- Abstract
Loading...
-
+
P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers
- Type: Poster Session
- Track: Biology
- Presentations: 53
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.06-035 - Study of the correlations between SNPs in angiogenic genes and treatment response/ outcome in patients with advanced NSCLC (non-squamous histology) treated in first line with carboplatin, paclitaxel and bevacizumab (CPB). The ANGIOMET study.
09:30 - 09:30 | Author(s): B. Massuti
- Abstract
Loading... -
+
P3.06-044 - KRAS, EGFR mutations and EGFR gene copy status as predictive markers of response and time to progression in EGFR wild-type stage IV non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine-kinase inhibitors.
09:30 - 09:30 | Author(s): M. Domine
- Abstract
Loading...
